Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Sep 5, 2023
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two approaches called Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) to help people who use multiple substances, including opioids and tobacco. The researchers want to understand how to effectively implement these techniques in clinics and see if they help participants reduce their use of opioids, tobacco, and other drugs. The trial is currently recruiting participants aged 18 and older who are English-speaking, currently on methadone, and smoke cigarettes.
If you join the study, you will participate in sessions designed to help you manage your substance use better. It's important to note that you will not be eligible if you have severe cognitive issues, are at risk of suicide, have previously trained in mindfulness, or are currently receiving treatments to quit smoking. This trial aims to find effective strategies to support individuals facing substance use challenges, and your participation could contribute to valuable insights in this important area of health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English-speaking
- • Age ≥18
- • Currently on methadone; and 4) currently smoke cigarettes.
- Exclusion Criteria:
- • Severe cognitive impairment (score \>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)
- • Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)
- • Inability to attend or fully participate in intervention sessions or assessments
- • Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33
- • Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling
- • Any contraindications for NRT
- • Currently or soon planning to be pregnant or breastfeeding.
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Nina Cooperman, PsyD
Principal Investigator
Rutgers Robert Wood Johnson Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported